Future oncology最新文献_第2页

Tissue-based PEG10 expression as an exploratory biomarker associated with first-line R-CHOP treatment outcome in diffuse large B-cell lymphoma. 基于组织的PEG10表达作为弥漫性大b细胞淋巴瘤一线R-CHOP治疗结果相关的探索性生物标志物

IF 3.1 4区医学

Future oncology Pub Date : 2026-10-06 DOI: 10.1080/14796694.2026.2739185

Dina I Hemdan, Salwa Sabet, Lobna Ezz El-Arab, Mohamed Alorabi, Haidan M El-Shorbagy, Nashwa El-Khazragy

{"title":"Tissue-based PEG10 expression as an exploratory biomarker associated with first-line R-CHOP treatment outcome in diffuse large B-cell lymphoma.","authors":"Dina I Hemdan, Salwa Sabet, Lobna Ezz El-Arab, Mohamed Alorabi, Haidan M El-Shorbagy, Nashwa El-Khazragy","doi":"10.1080/14796694.2026.2739185","DOIUrl":"https://doi.org/10.1080/14796694.2026.2739185","url":null,"abstract":"Aim: Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma, and 30-40% of patients develop primary resistance to first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This study evaluated tissue paternally expressed gene 10 (PEG10) expression as a biomarker of R-CHOP resistance.Patients and methods: Retrospective observational cohort study utilizes formalin-fixed, paraffin-embedded lymph node tissues from 70 patients with DLBCL, 30 with indolent B-cell lymphoma, and 20 normal controls. PEG10 transcript expression was measured by quantitative real-time PCR and protein expression by immunohistochemistry. Associations with clinicopathological characteristics, prognostic indices, and treatment response were assessed using multivariable logistic regression.Results: PEG10 transcript expression was higher in DLBCL than in indolent lymphoma and normal tissues. Elevated PEG10 expression was associated with advanced stage, poor ECOG performance status, higher International Prognostic Index scores, and R-CHOP resistance. Immunohistochemistry confirmed increased PEG10 protein expression in resistant tumors. PEG10 was not independently associated with resistance after adjustment (p = 0.163), whereas Ann Arbor stage remained independently associated (p = 0.042).Conclusion: Tissue PEG10 overexpression is associated with adverse clinicopathological features and unfavorable R-CHOP response and may serve as an exploratory complementary tissue-based biomarker in DLBCL. These findings require validation in larger prospective multicenter cohorts before clinical implementation in practice.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-13"},"PeriodicalIF":3.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective. Gedatolisib治疗激素受体阳性/ her2阴性晚期乳腺癌：欧洲视角

IF 3.1 4区医学

Future oncology Pub Date : 2026-10-05 DOI: 10.1080/14796694.2026.2742759

Letizia Matera, Julian David Etessami, Carmine Valenza, Giuseppe Curigliano

{"title":"Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective.","authors":"Letizia Matera, Julian David Etessami, Carmine Valenza, Giuseppe Curigliano","doi":"10.1080/14796694.2026.2742759","DOIUrl":"https://doi.org/10.1080/14796694.2026.2742759","url":null,"abstract":"Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC) represents the most common disease subtype. Although the introduction of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) has substantially improved patient outcomes, treatment resistance inevitably develops. Therapeutic options after progression on CDK4/6i-based regimens provide limited clinical benefit, particularly in patients without actionable target mutations. The PI3K/AKT/mTOR pathway drives endocrine and CDK4/6i resistance and of tumor progression, representing an attractive therapeutic target in this setting. Gedatolisib is a novel intravenous dual PI3K/mTOR inhibitor that simultaneously targets all class I PI3K isoforms and both mTOR complexes. Preclinical studies demonstrated broad antitumor activity irrespective of PIK3CA mutational status and enhanced activity when combined with ET and CDK4/6i. Early clinical trials reported preliminary antitumor activity, although associated with a considerable toxicity profile. More recently, the phase III VIKTORIA-1 trial demonstrated clinically meaningful PFS improvements with gedatolisib-based regimens in patients with HR+/HER2- metastatic BC pretreated with CDK4/6i, regardless of PIK3CA mutational status. This review summarizes the biological rationale, pharmacological profile, clinical development, and potential therapeutic positioning of gedatolisib in the evolving treatment landscape of HR+/HER2- metastatic BC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":3.1,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology. asco 2026后：住院医师主导的泌尿生殖肿瘤临床相关研究亮点。

IF 3.1 4区医学

Future oncology Pub Date : 2026-10-03 DOI: 10.1080/14796694.2026.2742677

Martina Izzi, Kristian Shtembari, Stefano Specchiarello, Chiara Calandrelli, Silvia Mancini, Marinella Micol Mela, Virginia Rossi, Roberta Giorgione, Daniele Rossini, Serena Pillozzi, Lorenzo Antonuzzo, Giandomenico Roviello

{"title":"Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology.","authors":"Martina Izzi, Kristian Shtembari, Stefano Specchiarello, Chiara Calandrelli, Silvia Mancini, Marinella Micol Mela, Virginia Rossi, Roberta Giorgione, Daniele Rossini, Serena Pillozzi, Lorenzo Antonuzzo, Giandomenico Roviello","doi":"10.1080/14796694.2026.2742677","DOIUrl":"https://doi.org/10.1080/14796694.2026.2742677","url":null,"abstract":"The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting presented important advances in genitourinary oncology. During a resident-led Post-ASCO GU 2026 meeting supervised by genitourinary oncology experts, clinically relevant studies were selected and critically discussed. This report reviews PROTEUS and TALAPRO-3 in prostate cancer; RAMPART and the KEYNOTE-564 circulating tumor DNA analysis in renal cell carcinoma; and POTOMAC, EV-302/KEYNOTE-A39, EV-303, and NEXUS-01 in urothelial carcinoma. These studies highlight the growing roles of perioperative systemic therapy, biomarker-guided treatment, antibody-drug conjugates, and patient-reported outcomes. Their clinical implications vary according to study design and evidence maturity: some reinforce established standards, whereas others support potential future strategies or remain hypothesis-generating. Although its educational impact was not formally assessed, the initiative provided a structured setting for discussing and critically appraising emerging congress evidence.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-5"},"PeriodicalIF":3.1,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma. DUBHE-H-308研究方案：基于iparomlimab和tuvonralimab （QL1706）的方案与sintilimab + bevacizumab作为晚期肝细胞癌一线治疗的随机、开放标签、无缝ii /III期试验的基本原理和适应性设计。

IF 3.1 4区医学

Future oncology Pub Date : 2026-10-01 DOI: 10.1080/14796694.2026.2739789

Fan Yang, Weikang Tao, Zihang Zhong, Jia Fan, Hao Yu, Shukui Qin

{"title":"DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma.","authors":"Fan Yang, Weikang Tao, Zihang Zhong, Jia Fan, Hao Yu, Shukui Qin","doi":"10.1080/14796694.2026.2739789","DOIUrl":"https://doi.org/10.1080/14796694.2026.2739789","url":null,"abstract":"No randomized trial has compared multiple immunotherapy-based combination strategies head-to-head in first-line advanced HCC, where approved doublet regimens achieve objective responses in fewer than one-third of patients. Iparomlimab and Tuvonralimab (QL1706), a new-type bifunctional combinedantibody (anti-PD-1/anti-CTLA-4 dual checkpoint inhibitor), deepens antitumor immunity while preserving tolerability. DUBHE-H-308 evaluates whether QL1706-based regimens, including a triplet with bevacizumab and oxaliplatin-based chemotherapy, can improve first-line outcomes in advanced HCC. DUBHE-H-308 (NCT05976568) is a prospective, randomized, open-label, multicenter, inferentially seamless phase II/III trial comparing three QL1706-based regimens against sintilimab plus bevacizumab in previously untreated advanced HCC. Three adaptive elements are incorporated: arm selection after phase II; seamless integration of phase II data into the phase III overall survival analysis; and a group-sequential interim analysis. Phase II co-primary endpoints are objective response rate and safety; the phase III primary endpoint is overall survival. Phase II enrollment is complete; interim data have guided regimen selection and confirmed transition to the confirmatory phase III stage. If successful, DUBHE-H-308 would provide the first randomized evidence supporting a triplet first-line strategy combining dual-checkpoint blockade, anti-VEGF therapy, and chemotherapy in advanced HCC, potentially establishing a new treatment standard. The adaptive framework maximizes efficiency without compromising confirmatory rigor.Clinical trial registration: ClinicalTrials.gov identifier NCT05976568.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy. SUNRAY-02：一项olomorasib联合免疫疗法治疗II-III期KRAS g12c突变型非小细胞肺癌的研究。

IF 3.1 4区医学

Future oncology Pub Date : 2026-10-01 DOI: 10.1080/14796694.2026.2736401

Jamie Chaft, Jay M Lee, Suresh Senan, Joel W Neal, Ernest Nadal, Marcelo V Negrao, Sanjay Popat, Marina C Garassino, Jhanelle E Gray, Se-Hoon Lee, Julien Mazieres, Michael Thomas, Martin Benes, Hui Liu, Jian Liu, Qinli Lily Ma, Grace Segall, Tarun Puri, Yi-Long Wu

{"title":"SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.","authors":"Jamie Chaft, Jay M Lee, Suresh Senan, Joel W Neal, Ernest Nadal, Marcelo V Negrao, Sanjay Popat, Marina C Garassino, Jhanelle E Gray, Se-Hoon Lee, Julien Mazieres, Michael Thomas, Martin Benes, Hui Liu, Jian Liu, Qinli Lily Ma, Grace Segall, Tarun Puri, Yi-Long Wu","doi":"10.1080/14796694.2026.2736401","DOIUrl":"https://doi.org/10.1080/14796694.2026.2736401","url":null,"abstract":"More than half of patients with early-stage non-small cell lung cancer (NSCLC) experience recurrent disease following definitive therapy. Targeted therapies have demonstrated significant and clinically meaningful benefit in EGFR-, ALK-, or RET-driven early-stage NSCLC. There are, however, no approved therapies for early-stage KRAS G12C-mutant NSCLC, presenting a potential therapeutic opportunity. Olomorasib is a potent, highly selective next-generation KRAS G12C inhibitor(i) demonstrating promising antitumor and intracranial activity with a manageable safety profile in KRAS G12C-mutant metastatic NSCLC. Preclinical studies have shown that KRAS G12C inhibition reverses KRAS-mediated immune suppression, creating an inflamed tumor microenvironment responsive to immunotherapy. Combining olomorasib and immune checkpoint inhibitors is supported by synergistic and additive effects in preclinical and clinical setting. SUNRAY-02 is a 2-part global, placebo-controlled phase III study recruiting patients with stage II-III KRAS G12C-mutant NSCLC following definitive therapy. Part A patients with resected NSCLC receive olomorasib or placebo in combination with pembrolizumab, while Part B patients with unresectable NSCLC receive olomorasib or placebo in combination with durvalumab. Combination treatment continues for approximately 1-year, followed by olomorasib or placebo monotherapy, completing up to 3-years of treatment. This trial addresses a critical treatment gap in KRAS G12C-mutant early-stage NSCLC.Clinical trial registration: NCT06890598 (www.clinicaltrials.gov); EudraCT: 2024-512302-25-00.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors. star -311：赞扎替尼与依维莫司治疗晚期神经内分泌肿瘤的随机II/III期研究

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-28 DOI: 10.1080/14796694.2026.2733790

Jennifer A Chan, Jonathan R Strosberg, Changhoon Yoo, Simron Singh, Huang Huang, Manika Goel, Christian Scheffold, Jaume Capdevila

{"title":"STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors.","authors":"Jennifer A Chan, Jonathan R Strosberg, Changhoon Yoo, Simron Singh, Huang Huang, Manika Goel, Christian Scheffold, Jaume Capdevila","doi":"10.1080/14796694.2026.2733790","DOIUrl":"https://doi.org/10.1080/14796694.2026.2733790","url":null,"abstract":"Patients with advanced neuroendocrine tumors (NETs) experience poor outcomes despite the use of available therapies, including molecularly targeted agents. Zanzalintinib is a novel, small-molecule inhibitor of multiple kinases, including the TAM kinases (TYRO3, AXL, MER), MET, and vascular endothelial growth factor receptors, which play important roles in oncogenic processes. Zanzalintinib has shown encouraging antitumor activity and a consistent safety profile across multiple solid tumor types in clinical trials. STELLAR-311 is a global, randomized, open-label, phase II/III trial evaluating the efficacy and safety of zanzalintinib versus everolimus in patients with advanced NETs. Adults aged ≥18 years with locally advanced/unresectable or metastatic, well-differentiated grade 1-3 NETs of pancreatic (pNET) or extra-pancreatic (epNET; gastrointestinal tract, lung, thymus, or other) origin will be enrolled. Patients with pNETs or nonfunctional epNETs can be untreated or have received up to one prior line of therapy (excluding somatostatin analogs); patients with functional epNETs must have received one prior line of therapy. The primary endpoint is progression-free survival (PFS), by blinded independent central review (BICR). Secondary endpoints include overall survival; investigator-assessed PFS; BICR- and investigator-assessed objective response rate, duration of response, and disease control rate; safety; and quality of life.Clinical trial registration www.clinicaltrials.gov identifier is NCT06943755.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-8"},"PeriodicalIF":3.1,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-27 DOI: 10.1080/14796694.2026.2740314

引用次数: 0

Is neoadjuvant therapy redefining the surgeon's role in melanoma? 新辅助治疗是否重新定义了外科医生在黑色素瘤中的作用？

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-24 DOI: 10.1080/14796694.2026.2737581

Roger Olofsson Bagge

引用次数: 0

Beyond survival: advancing psycho-oncology research on fear of recurrence or progression. 超越生存：推进对复发或进展恐惧的心理肿瘤学研究。

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-23 DOI: 10.1080/14796694.2026.2735120

Anne Brédart, Pauline Bugeon, Céline Bodelet, Morgan Dondin, Anita Muller, Sébastien Simard, Sylvie Dolbeault

引用次数: 0

Review of evidence and future directions following the TUBA study: a long-term prospective preference study comparing risk-reducing salpingectomy with delayed oophorectomy to salpingo-oophorectomy. 回顾TUBA研究的证据和未来方向：一项长期前瞻性偏好研究，比较降低风险的输卵管切除术和延迟卵巢切除术与输卵管卵巢切除术。

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-23 DOI: 10.1080/14796694.2026.2736402

Fabienne C Lof, Tamar A Gootzen, C Marleen Kets, Marleen M H J van Gelder, Majke H D van Bommel, Michiel Simons, Rosella P M G Hermens, Miranda P Steenbeek, Joanne A de Hullu

引用次数: 0